Sarepta Therapeutics could move big on Monday
All eyes and ears will be focused this week on the JPM20 conferences at which SRPT is expected to possibly give a pre-announcement on earnings and a Drug Trial Update on Monday. These events can move a stock very fast and the option market is already implying a 6.5% move in the stock.
Short interest in the company is high at !7% which could led to quiet a rally on any positive updates.
Average Recommendation: BUY Average Target Price: 196.86
23 Buy
2 Overwight
1 Hold
0 Sell
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Short interest in the company is high at !7% which could led to quiet a rally on any positive updates.
Average Recommendation: BUY Average Target Price: 196.86
23 Buy
2 Overwight
1 Hold
0 Sell
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.